Researchers have developed a new blood test that measures the accumulation of tau protein tangles to better track the progression of Alzheimer’s disease, according to a study published in JAMA.
The test, created in collaboration with Alamar Biosciences, measures levels of a biomarker called eMTBR-tau. While current blood tests typically detect proteins like beta-amyloid and phosphorylated tau that rise during the early stages of the disease, they provide limited information regarding the buildup of tau tangles in later stages, Reuters reported.
“Having a simple yet highly scalable way to determine the extent of tau tangle buildup in the brain represents a major step forward in our understanding of Alzheimer’s,” said Nicholas Ashton, study co-leader and senior director of the Banner Sun Health Research Institute in Sun City, Arizona.
Identifying advanced pathology
The study, which included 521 brain donors in two U.S. autopsy cohorts and 207 participants in imaging studies, found that the new immunoassay accurately identified advanced tau pathology. To assess the immunoassay, researchers examined blood from 207 participants in Canadian and Swedish imaging studies along with 521 brain donors from two U.S. autopsy cohorts.
The performance of the test was comparable to more complex mass spectrometry methods, Inside Precision Medicine reported. Medscape said that both techniques achieved similarly high accuracy in identifying regional tau-PET positivity, with AUCs of 0.96 to 0.99 for the immunoassay and 0.97 to 0.99 for mass spectrometry.
In the autopsy cohorts, eMTBR-tau concentrations were significantly higher in individuals with the most advanced neurofibrillary tangle pathology. Specifically, at Braak stage VI—where tau tangles have spread into the cerebral cortex—levels were 25.2 to 50.5 times higher than at stages I–II, Medscape noted.

In the two cohorts studied, eMTBR-tau levels at Braak stage VI were 50.5-fold and 25.2-fold higher than at stages I-II, both yielding a P value of less than 0.001.
“One of the most challenging tasks in Alzheimer’s disease diagnosis is to establish in a patient with cognitive impairment that Alzheimer’s pathology is not just present, but that is present in a sufficiently advanced biological stage to be a likely explanation for symptoms,” said Niklas Mattsson-Carlgren, head of the study team from Lund University in Sweden.
The immunoassay offers a more practical alternative to current specialized methods. Previously, measuring the biomarker required specialized mass spectrometry that was only available in relatively few laboratories. The new test offers a scalable approach to determining the extent of tau tangle buildup.
Alzheimer's biomarkers
Alzheimer’s disease is the most common form of dementia, representing roughly 60% to 80% of all cases. The World Health Organization reports that the global number of patients has surpassed 50 million and is expected to reach 152 million by 2050. The disease is characterized by two main pathological hallmarks: amyloid-beta plaques and neurofibrillary tangles made of aggregated tau protein.
In 2024, the National Institute on Aging and Alzheimer’s Association (NIA-AA) issued revised Diagnostic and Staging Criteria. This update officially incorporated core blood biomarkers, such as plasma p-tau217, into the diagnosis and staging system, transitioning the framework from ATN to ATNIVS.
Research findings from the 2025 Alzheimer’s Association International Conference (AAIC) indicated that the sensitivity and specificity of Alzheimer’s blood testing indicators have both exceeded 90%, meeting the “dual 90%” standard. This level of performance may allow these tests to replace expensive PET-CT imaging and invasive CSF testing.
While p-tau217 is a measure of soluble tau pathology used to identify amyloid pathology, it is less specific for the insoluble tau tangles that track neurodegeneration and cognitive decline. Studies published in 2025 and 2026 have linked higher concentrations of eMTBR-tau to faster cognitive decline and tau accumulation.
Complementing existing biomarkers
Researchers emphasized that this new test is not intended to replace current diagnostic tools but to work alongside them. Existing tests measuring p-tau217 can identify early Alzheimer’s-related amyloid pathology, while eMTBR-tau can provide information on how far the tau tangles have spread.
“P-tau217 and eMTBR-tau are likely complementary, and there may eventually be a series or panel that could measure and help with staging of someone’s underlying biology,” the researchers said.
Tatiana Marcal, MD, who serves as the senior director of medical affairs and clinical programs at the Alzheimer’s Association, said that eMTBR-tau might one day serve to complement, rather than replace, current blood biomarkers. She said that such progress supports a more precise and personalized approach to Alzheimer’s and other dementias.

Scaling this testing could change how clinical and research settings operate. Medscape reported that the authors believe this “scalable immunoassay could broaden research access and support clinical evaluation.”
Ashton added that the combined use of existing tests and the new eMTBR-tau test could help doctors make better treatment decisions and identify the right patients for clinical trials. This is particularly relevant as several drugs currently in development are designed to target the tau protein, while two existing drugs on the market target beta-amyloid plaques.
Experts recommend plasma p-tau217 for Alzheimer's pathology
While blood biomarkers are emerging as promising tools for providing molecular evidence of Alzheimer’s pathology, professional organizations have issued specific guidance on their use. To establish a consensus regarding the proper application of these biomarkers, a panel of experts from the Royal College of Psychiatrists (RCPsych) Old Age Faculty and the Association of British Neurologists (ABN) Cognitive Advisory Group met.
The guidance recommends using plasma p-tau217 as the blood biomarker of choice, provided there is appropriate sample handling and laboratory processing. However, experts advise that Alzheimer’s disease biomarkers should not be used as stand-alone diagnostic tests.
Instead, they should serve as an adjunct to a comprehensive clinical assessment. Testing is considered appropriate only when Alzheimer’s is suspected on clinical grounds, and it should not be used to measure asymptomatic individuals except within a research context.

Implementation remains a challenge in some healthcare systems. Because these tests are not widely available, less than 5% of dementia diagnostic services within the National Health Service (NHS) have managed to adopt this guidance.
Clinicians are advised not to use blood biomarker testing to triage patients for seeing a dementia expert. Professionals should discuss the purpose and possible outcomes of testing with patients before proceeding, and communicate results within the context of a full clinical assessment, maintaining openness about diagnostic uncertainty.
Larger prospective studies are still required to establish clinical cutoffs, validate performance across different laboratories, and determine if the test can predict treatment response or cognitive decline.
Earlier coverage: AriBio Pill Slows Alzheimer's Decline in Monotherapy Group, Trial Finds